Alimera Sciences Inc  

(Public, NASDAQ:ALIM)   Watch this stock  
Find more results for ALIM
1.09
+0.03 (2.36%)
Real-time:   10:00AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.05 - 1.10
52 week 1.01 - 5.15
Open 1.05
Vol / Avg. 39,909.00/313,028.00
Mkt cap 47.15M
P/E     -
Div/yield     -
EPS -0.72
Shares 45.10M
Beta 2.00
Inst. own 89%
Aug 8, 2016
Q2 2016 Alimera Sciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 12, 2016
Alimera Sciences Inc at Cantor Fitzgerald Healthcare Conference
Jun 24, 2016
Alimera Sciences Inc Annual Shareholders Meeting (Estimated)
Jun 23, 2016
Alimera Sciences Inc Annual Shareholders Meeting
Jun 8, 2016
Alimera Sciences Inc at LD Micro Invitational Conference
May 23, 2016
Alimera Sciences Inc at UBS Global Healthcare Conference
May 5, 2016
Q1 2016 Alimera Sciences Inc Earnings Call
May 4, 2016
Q1 2016 Alimera Sciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -192.12% -136.58%
Operating margin -195.72% -173.81%
EBITD margin - -162.42%
Return on average assets -67.48% -34.21%
Return on average equity - -
Employees 125 -
CDP Score - -

Address

6120 Windward Pkwy Ste 290
ALPHARETTA, GA 30005-8897
United States - Map
+1-678-9905740 (Phone)
+1-678-9905744 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Officers and directors

Richard S. Eiswirth Jr. President, Chief Financial Officer
Age: 46
Bio & Compensation  - Reuters
C. Daniel Myers Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Kenneth E Green Ph.D. Senior Vice President, Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
David R Holland Senior Vice President - Sales and Marketing
Age: 51
Bio & Compensation  - Reuters
Philip Ashman Senior Vice President, European Managing Director
Age: 50
Bio & Compensation  - Reuters
David Burke Vice President
Bio & Compensation  - Reuters
Mark J. Brooks Independent Director
Age: 48
Bio & Compensation  - Reuters
Brian K. Halak Ph.D. Independent Director
Age: 44
Bio & Compensation  - Reuters
James R. Largent Independent Director
Age: 65
Bio & Compensation  - Reuters
Peter J. Pizzo III Independent Director
Age: 48
Bio & Compensation  - Reuters